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doi:10.1016/j.jmii.2011.09.029Background: The purpose of this study is to delineate clinical characteristics of urosepsis caused
by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae
(ESBL-EK) in different clinical settings, with an emphasis on community-acquired infections.
Methods: A retrospective study was conducted at two medical centers in Taiwan. From May 2002
to August 2007, clinical data of adults with urosepsis caused by ESBL-EK were collected. Patients
were categorized into three groups according to the place of acquisition. Baseline characteristics,
microbiological data and clinical outcomes were compared.
Results: Ninety-three cases of ESBL-EK urosepsis were included. Their mean age was 69.4 years,
and 48.4% were men. Eleven (11.8%), 41 (44.1%), and 41 (44.1%) patients were categorized ast of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan
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128 J.-C. Lee et al.having community-acquired, healthcare-associated, and hospital-acquired infections, respec-
tively. Cases of ESBL-EK urosepsis from different settings shared similar characteristics in terms
of age, gender, comorbidity and resistance profiles of bacterial strains. Of the bacterial isolates,
75% and 38.7% were resistant to fluoroquinolones and aminoglycosides, respectively. Cases of
community-acquired urosepsis had a lower disease severity than those acquired in healthcare
facilities or hospitals. Of note, there was no case fatality in 11 cases of community-acquired
urosepsis and, in contrast, a crude mortality rate of 41.5% was found among adults with
hospital-acquired urosepsis (p < 0.001).
Conclusion: A limited number of adults with community-acquired urosepsis caused by ESBL-EK in
the present study had a favorable outcome. Nonetheless, clinicians should be cautious of the
emergence of urinary tract infections caused by ESBL-producers in the community setting.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Since an extended-spectrum beta-lactamase (ESBL)-
producing organism was first reported in Germany in 1983,1
the worldwide spread of pathogens harboring this charac-
teristic phenotype, hydrolyzing most broad-spectrum beta-
lactam agents, had a serious impact on the clinical
management of infection diseases.2 ESBL-producer infec-
tion has been known to be associated with a worse outcome
than non-ESBL producer infection.3 Besides, patients with
ESBL-producer infections were more likely to receive
inappropriate empirical antimicrobial therapy, which would
be associated with a grave outcome.3
Escherichia coli and Klebsiella pneumoniae are two
common ESBL-producing Enterobacteriaceae found world-
wide,4 and cause various infections, such as urinary tract
infections (UTIs), intra-abdominal infections, and bacter-
emia in both nosocomial and community settings.3,5,6 Yu et al
summarized the published data about the epidemiology of
ESBL-producing Enterobacteriaceae in Taiwan; the preva-
lence of the ESBL-producing phenotype among clinical E. coli
or K. pneumoniae isolates ranged from 1.5% to 29.8% before
2005.7 A recent study conducted in a tertiary center in Taiwan
has shown that ESBL-producing E. coli and K. pneumoniae
(ESBL-EK) accounted for 20.7% of the pathogens causing
bacteremic community-onset UTIs.8 Without exception, the
increasing prevalence of ESBL-production among clinical
E. coli and K. pneumoniae isolates was noted in our hospital
(data not shown). Therefore, clinicians should be aware of
potential treatment failure for community-acquired infec-
tions caused by ESBL-producing pathogens, as empirical use
of cephalosporins is a common practice in Taiwan. The
present study is focused on urosepsis and designed to depict
the clinical specialty of ESBL-producer infections originating
from the community by comparing with those of healthcare-
associated and hospital-acquired urosepsis.Materials and methods
Patients
A retrospective study was conducted in two medical
centers, National Taiwan University Hospital (Hospital A)and National Cheng Kung University Hospital (Hospital B), in
Taiwan. The list of patients with ESBL-EK bacteremia
between May 2002 and August 2007 was retrieved from the
database of Clinical Microbiology Laboratories in the two
study hospitals. Cases of ESBL-EK bacteremia fulfilling the
following criteria were included for analysis: adults (aged
older than 18 years) with either symptoms of lower UTIs or
pyuria associated with the same pathogen as that found in
the bloodstream (defined as the same bacterial species
with the same antibiogram). For patients having more than
one episode of bacteremia caused by the same isolate, only
the first bacteremic episodes were included for analysis.
Antimicrobial susceptibility and ESBL detection of
bacterial isolates
Blood samples collected in the commercially prepared
bottles were incubated in blood culture system (BACTECTM
9240, Beck Dickinson, New Jersey, USA). Urine samples
were plated onto the chromogenic medium (ChromID CPS3,
bioMe´rieux, Marcy l’Etoile, France). E. coli and K. pneu-
moniae isolates were identified by the colony/biochemical
characters and confirmed by the Vitek identification system
(bioMe´rieux).
Antimicrobial susceptibility of each isolate was deter-
mined by the disk diffusion method, employing the method
and interpretative criteria recommended by the Clinical and
Laboratory Standards Institute (CLSI).9 Phenotypic confir-
mation for ESBL detection was performed by cephalosporin/
clavulanate combination disks as suggested by the CLSI.
Collection of clinical information
Medical records of eligible cases were reviewed. Clinical
information, including demographic data, comorbidities,
disease severity, complication of bacteremia, laboratory
and microbiology data, antimicrobial treatment, and clin-
ical outcome, was collected using a standardized case form.
Definitions
UTIs with concurrent bacteremia caused by the same
pathogen indicated the presence of urosepsis. Complicated
ESBL-producing Enterobacteriaceae urosepsis 129urosepsis was arbitrarily defined as urosepsis complicated
by functional or structural lesions of the urinary tract,
infections involving the prostate, or abscess formation.
Based on the place of acquisition, urosepsis was classified
into three groups, i.e., community-acquired, healthcare-
associated, or hospital-acquired urosepsis. The hospital-
acquired urosepsis comprised adults with positive cultures
that were obtained after more than 48 hours of hospitaliza-
tion. Healthcare-associated infections followed the defini-
tion made by Friedman et al10 In brief, individuals who had
visited a hemodialysis clinic or received intravenous chemo-
therapy in the 30 days before the onset of bacteremia, were
hospitalized in an acute care hospital for 2 days ormore in the
90 days before bacteremia, or resided in a long-term care
facility, were regarded to have healthcare-associated infec-
tions. Community-acquired urosepsis comprised patients
unable to fulfill the definitions of health care-associated and
hospital-acquired infections. Blood and/or urine samples
with ESBL-EK had to be obtainedwithin 48 hours of admission
among adults with healthcare-associated or community-
acquired urosepsis. ESBL-EK isolates conferring resistance
tobothfluoroquinolones (either ciprofloxacinor levofloxacin,
or both) and aminoglycosides (either amikacin or gentamicin,
or both) were defined as being multidrug resistant (MDR).
The severity of bacteremia was evaluated by the Pitts-
burgh bacteremia score, andpatientswith four points ormore
were regarded as having critical illness.11 Organ dysfunctions
involving cardiovascular, respiratory, renal, hepatic, neuro-
logical, or hematological systems were classed as having
clinical worst conditions within the first 24 hours after
bacteremia onset, and evaluated by the organ dysfunction
and/or infection score.12 Patients with dysfunction in two or
more organs were categorized as having severe sepsis.
Empirical antimicrobial therapy was defined as the drugs
administrated within 48 hours of bacteremia onset. Types
of antimicrobial agents were classified into carbapenems,
cephalosporins, cephamycins, fluoroquinolones, and b-
lactam/b-lactamase inhibitor combinations. The definitiveTable 1 Baseline characteristics of 93 patients with extended-
siella pneumoniae urosepsis acquired in different clinical setting
Variables
Community-acquired
(n Z 11)
Gender (male) 5 (45.5)
Elderly (>65 years) 7 (63.6)
Comorbidities 8 (72.7)
Diabetes mellitus 5 (45.5)
Chronic kidney disease 4 (36.4)
Malignancy 2 (18.2)
Regular dialysis 0
Immunosuppressant therapy 0
Chemotherapy 0
Steroid 0
Organ transplantation 0
Chronic hepatitis 0
Liver cirrhosis 0
HIV infection 0antimicrobial therapy was determined by the drugs admin-
istrated after the microbiological data were available.
Antimicrobial agents were considered to be appropriate if
the causative bacterium was susceptible to the agent,
according to the antimicrobial susceptible data. The clinical
outcomes considered in the study included mortality at
discharge, 30-day crude mortality, and sepsis-related
mortality, which was defined as the death of patients with
persisting clinical evidences of active infection, excluding
other causes of mortality.
Statistic analysis
Variables of clinical information were computed and were
analyzed with SPSS software for Windows, version 13.0.
Categorical variables were expressed as percentages of
each subgroup of patients, and compared by the X2 test
with or without Fisher exact test or Yate’s continuity
correction. The variables with a p value less than or equal
to 0.1 in the univariate analysis were put into the multi-
variable analysis. A p value less than 0.05 was considered to
be statistically significant, and all tests were two-tailed.
Results
During the study period, 93 patients fulfilling the eligible
criteria were analyzed. Their mean age was 69.4 years and
48.4% were male. With respect to the clinical settings where
ESBL-EK urosepsis developed, 11(11.8%) were community-
acquired, 41 (44.1%) were healthcare-associated, and 41
(44.1%) were hospital-acquired. Baseline characteristics of
93 patients with ESBL-EK urosepsis are shown and compared
in Table 1. There was no difference in age, gender, or
comorbid conditions between groups. Diabetes mellitus and
chronic kidney disease were common underlying diseases
in the three groups. In patients with healthcare-associated
and hospital-acquired infections, debilitating comorbiditiesspectrum beta-lactamase-producing Escherichia coli or Kleb-
s
Number of cases (%) p
Healthcare-associated
(n Z 41)
Hospital-acquired
(n Z 41)
18 (43.9) 22 (53.7) 0.662
24 (58.5) 30 (73.2) 0.374
34 (82.9) 34 (82.9) 0.713
18 (43.9) 21 (51.2) 0.796
15 (36.6) 18 (43.9) 0.771
13 (31.7) 12 (29.3) 0.680
5 (12.2) 11 (26.8) 0.034
4 (9.8) 8 (19.5) 0.167
3 (7.3) 2 (4.9) 0.622
1 (2.4) 5 (12.2) 0.129
0 2 (4.9) 0.274
6 (14.6) 3 (7.3) 0.274
6 (14.6) 3 (7.3) 0.274
0 1 (2.4) 0.527
130 J.-C. Lee et al.other than diabetes mellitus and chronic kidney disease,
such as malignancies, immunosuppressant therapy, or liver
cirrhosis, were noted more often than in patients with
community-acquired infections (51.2% and 63.4% vs. 18.2%,
respectively, p Z 0.028).
In total, 59 patients were from Hospital A and 34 from
Hospital B. There were no differences between cases from
Hospitals A and B in terms of age, gender, and comorbidities.
The proportions of E. coli and K. pneumoniae were similar in
the two hospitals. Ten (91%) of 11 cases with community-
acquired infection were noted in Hospital A. However,
infections in patients from Hospital B were more severe than
in those from Hospital A, as indicated by a Pittsburgh
bacteremia score 4 (35.3% vs. 15.3%, p Z 0.039). More
patients from Hospital A received empirical carbapenem
therapy than from Hospital B (39.0% vs. 17.6%, pZ 0.038).
Carbapenems were empirically prescribed to treat the
bloodstream infections in 36.4% of community-acquired
infections, 24.4% of health care-associated infections and
36.6% of hospital-acquired infections (p Z 0.455). Micro-
biological characteristics of those ESBL-EK isolates are
shown in Table 2. The MDR phenotype was present in 37.6%
of 93 isolates. More bacterial isolates from healthcare-
associated infections were resistant to either aminoglyco-
sides (51.2% vs. 27.3% or 29.3%) or fluoroquinolones (82.9%
vs. 54.5% or 73.2%) than those from community-acquired
infections or hospital-acquired infections, though the
differences were not statistically significant (pZ 0.088 and
0.14, respectively; Table 2).
Concerning the severity of the bloodstream infections,
fewer cases with community-acquired ESBL-EK urosepsis
presented with organ dysfunction than those in the other
two groups (Table 3). In contrast, hospital-acquired infec-
tions were more often associated with acute renalTable 2 Empirical antibiotics prescribed for patients with exte
Klebsiella pneumoniae urosepsis and microbiological characterist
Variables
Community-ac
(n Z 11)
Empirical treatment
Cephalosporins 3 (27.3)
Carbapenems 4 (36.4)
Fluoroquinolones 2 (18.2)
b-lactam/b-lactamase inhibitors combinations 1 (9.1)
Cephamycins 1 (9.1)
Others 0
Appropriate empirical therapy 4 (36.4)
Appropriate definitive therapy 9 (81.8)
Microbiological characteristics
Species
E. coli 9 (81.8)
K. pneumoniae 2(18.2)
Polymicrobial bacteremia 1 (9.1)
Multidrug resistance 3 (27.3)
Fluoroquinolone resistance a 6 (54.5)
Aminoglycoside resistance b 3 (27.3)
a Resistant to levofloxacin or ciprofloxacin.
b resistant to amikacin or gentamicin.dysfunction (p Z 0.001) or respiratory failure (p Z 0.005).
In terms of sepsis-related mortality, no fatality occurred in
cases with community-acquired infections, compared to
4.9% of patients with healthcare-associated infections and
14.6% of patients with hospital-acquired infections, though
the difference did not reach the statistical significance
(pZ 0.161). Likewise, there were no significant differences
in the 30-day mortality rates between the three groups.
This was despite a higher 30-day mortality rate of 17.1% in
cases with hospital-acquired infections compared to those
with healthcare-associated (7.3%) or community-acquired
(0%) infections (p Z 0.171). As for the discharge mortality
rate, hospital-acquired infection was significantly higher
(41.5%) than healthcare-associated (9.8%) or community-
acquired infections (0%) (p < 0.001).
To identify the prognostic factors of clinical aspects,
clinical data of survival cases and fatal cases associated
with sepsis are compared in Table 4. A high Pittsburgh
bacteremia score (4) [odds ratio (OR) 20.55, 95% confi-
dence interval (CI) 3.31e127.37, p Z 0.001], shock (OR
9.86, 95% CI 1.17e83.01, p Z 0.04), and neurological
failure (OR 11.29, 95% CI 1.62e78.88, p Z 0.02), were
independently associated with sepsis-related mortality. In
contrast, male gender (OR 0.08, 95% CI 0.01-0.79,
p Z 0.031) was related to a favorable outcome. Appropri-
ateness of empirical or definitive therapy was not signifi-
cantly related to a favorable outcome in terms of sepsis-
related mortality.Discussion
Bacteremia caused by ESBL-producing Enterobacteriaceae
has been known to be associated with a longer hospital staynded-spectrum beta-lactamase-producing Escherichia coli or
ics of causative isolates
Number of cases (%) p
quired Healthcare-associated
(n Z 41)
Hospital-acquired
(n Z 41)
24 (58.5) 18 (43.9) 0.136
10 (24.4) 15 (36.6) 0.455
1 (2.4) 4 (9.8) 0.164
5 (12.2) 2 (4.9) 0.497
0 2 (4.9) 0.230
1 (2.4) 0 0.527
11 (26.8) 19 (46.3) 0.186
30 (73.2) 31 (75.6) 0.838
0.403
25 (61.0) 25 (60.9)
16 (39.0) 16 (39.0)
11 (26.8) 7 (17) 0.335
20 (48.8) 12 (29.3) 0.143
34 (82.9) 30 (73.2) 0.140
21 (51.2) 12 (29.3) 0.088
Table 3 Severity of disease and mortality of 93 patients with extended-spectrum beta-lactamase-producing Escherichia coli
or Klebsiella pneumoniae urosepsis in three different clinical settings
Variables Number of cases (%) p
Community-acquired
(n Z 11)
Healthcare-associated
(n Z 41)
Hospital-acquired
(n Z 41)
Severity
Pittsburgh bacteremia score 4 0 9 (22.0) 12 (29.3) 0.118
Severe sepsis a 0 8 (19.5) 10 (24.4) 0.191
ODIN scoreb defined organ failure
Respiratory failure 0 5 (12.2) 15 (36.6) 0.005
Shock 0 12 (29.3) 14 (34.1) 0.079
Hematological failure 1 (9.1) 7 (17.1) 7 (17.1) 0.796
Neurological failure 0 7 (17.1) 7 (17.1) 0.331
Renal failure 0 13 (31.7) 2 (4.9) 0.001
Hepatic failure 0 4 (9.8) 1 (2.4) 0.239
Complicated urosepsisc 3 (27.3) 7 (17.7) 6 (14.6) 0.569
Mortality
Sepsis-related mortality 0 2 (4.9) 6 (14.6) 0.161
30-day crude mortality 0 3 (7.3) 7 (17.1) 0.171
Mortality at discharge 0 4 (9.8) 17 (41.5) <0.001
a Two or more organ systems failure.
b Organ damage and/or infection score.
c Urosepsis complicated with structural or functional dysfunction, prostate involvement, or abscess formation. ODIN Z organ
dysfunction and/or infection.
ESBL-producing Enterobacteriaceae urosepsis 131and incomplete treatment response.13 In the community-
onset cases, it is also related to early in-hospital
mortality.3,8 Since the emergence of ESBL-producer infec-
tions in the community, a question is elicited: should
clinicians prescribe antimicrobial agents with a more broad
antibacterial spectrum to treat patients coming from the
community? A major concern of such a clinical practice is
that the extended use of broad-spectrum antimicrobial
agents may contribute to the spread of antimicrobial
resistant pathogens.14 The balance between the pros and
cons of antimicrobial treatment becomes an importantTable 4 Variables associated with the sepsis-related mortality
beta-lactamase-producing Escherichia coli or Klebsiella pneumon
Variables Number of cases (%)
Fatal
(n Z8)
Surviving
(n Z85)
Odd
rat
Gender (male) 1 (12.5) 44 (51.8) 0.1
Comorbidities other than DM or CKD 7 (87.5) 42 (49.4) 7.1
Pittsburgh bacteremia score 4 6 (75) 15 (17.6) 14.
Severe sepsis 7 (87.5) 11 (12.9) 47.
Shock 6 (75) 20 (23.5) 9.7
Respiratory failure 4 (50) 16 (18.8) 4.3
Hematological failure 4 (50) 11 (12.9) 6.7
Neurological failure 5 (62.5) 9 (10.6) 14.
Hepatic failure 2 (25) 3 (3.5) 9.1
Appropriate definitive therapy 3 (37.5) 67 (78.8) 0.1
Appropriate empirical therapy 1 (12.5) 33 (38.8) 0.2
Community-acquired infections 0 11 (12.9) d
CKD Z chronic kidney disease; DM Z diabetes mellitus.issue. It is important to find clinical clues for early identi-
fying people with infectious diseases caused by ESBL-
producing Enterobacteriaceae and early initiation of
appropriate antimicrobial therapy.
Risk stratification is important in the initial evaluation
of clinical cases and subsequent management. However,
the retrospective nature and study design of the present
study made us unable to identify the risk factors of ESBL-
producer infections among individuals with community-
onset infections. In the literature, several risk factors
for ESBL-producing bacterial infections have been wellamong patients with urosepsis caused by extended-spectrum
iae
Univariate analysis Multivariate analysis
s
io
95% confidence
interval
p Odds
ratio
95% confidence
interval
p
3 0.02-1.13 0.060 0.08 0.01-0.79 0.031
7 0.85-60.79 0.062
00 2.57-76.23 0.001 20.55 3.31e127.37 0.001
09 5.28-420.31 <0.001
5 1.82-52.16 0.005 9.86 1.17e83.01 0.023
1 0.97-19.11 0.062
3 1.47-30.88 0.022
07 2.87-68.97 <0.002 11.29 1.62e78.88 0.015
1 1.27-65.46 0.057
6 0.04-0.74 0.021
3 0.03-1.91 0.250
d 0.589 0.999
132 J.-C. Lee et al.described.3,13,15,16 In the clinical settings of community-
onset infections, ESBL-producer infections were usually
associated with old age,3,16 urinary tract anomaly or
catheter use,3 previous hospitalization,3,16 and recent
exposure to antimicrobial agents.3,15,16 These characters
implicate the close linkage between cases and health care
facilities. In our study, we applied the Friedman’s defini-
tion for health care-associated infections. Cases with
residence in health care facilities and/or a recent hospital
stay would not be included in the group of community-
acquired urosepsis. Therefore, our patients with
community-acquired urosepsis can be regarded to acquire
the infections in the community. Although diabetes melli-
tus and chronic kidney disease were frequently noted, fewer
or no other debilitating conditions, such as malignancy, liver
cirrhosis, or immunosuppressant therapy, were ever impli-
cated in the cases of community-acquired infections. These
conditions were, however, more commonly present in those
with healthcare-associated or hospital-acquired infections.
Fewer underlying illnesses may be partially associated with
a favorable prognosis for community-acquired urosepsis in
our study.
In this study, in accordance with previous studies,17e19
Pittsburgh bacteremia score-defined critical illness was
noted to be the independent prognostic factor, as well as
the presence of shock and neurological failure. Of note, the
severity of disease and frequencies of organ dysfunctions at
the initial presentation of bacteremia were lower in the
community-acquired group than the other two groups.
There was no fatal case in the community-acquired group.
Beyond these host factors, we speculate that the favorable
outcome of the community-acquired infections may be
partly contributed to the virulence factors of bacteria. A
trade-off between the resistance and virulence20 has been
mentioned. That is, the more resistance, the less virulence.
Another plausible explanation for favorable outcome in the
community-acquired subgroup of ESBL-producer urosepsis
is the absence of debilitating underlying conditions, which
may play a critical role in determining the clinical outcome
of bloodstream infections.
Previous clinical studies on community-onset infections
caused by ESBL-producing Enterobacteriaceae have shown
conflicted results regading the impact of the appropriate-
ness of empirical therapy on mortality.3,13,17,21 Diverse
study designs and different categorization of clinical
settings made the data incomparable. In our study, neither
empirical nor definitive antimicrobial therapy were signifi-
cantly related to the sepsis-related mortality. However,
there was a trend for a better outcome in those treated by
appropriate empirical or definitive antimicrobial therapy.
The limited sample size made this study unable to clearly
elucidate the role of antimicrobial therapy on the outcome
of cases of ESBL-producer blood stream infections.
However, at the present time it is too early to change the
current recommendation for community-acquired UTIs with
the increasing concern of ESBL-producer infections, since
our patients with community-acquired urosepsis caused by
ESBL-producers fared well in spite of about two-thirds of
these patients not empirically receiving appropriate anti-
microbial therapy.
ESBL production renders most beta-lactam agents inef-
fective, and the phenomenon of co-resistance to otherclasses of antimicrobial agents existing in these pathogens
further limits the therapeutic choice of antimicrobial agents
for ESBL-producer infections.22,23We found the co-resistance
pattern of community-acquired ESBL-producers was similar
to that of isolates obtained in healthcare-associated or
hospital-acquired infections. Though not proven in the
present study, it is possible that there is overflow of noso-
comial ESBL-producers into the community.24e26
In conclusion, our study highlights that there was an
emergence of urosepsis due to ESBL-producing Enter-
obacterieaceae in the community, and the affected
subjects had clinical characteristics of lower disease
severity, less chronic debilitating illness, and a favorable
prognosis. More clinical observations are required to
delineate the clinical impact of ESBL-producer infections in
the community setting.References
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